Status:
UNKNOWN
Intravenous Buprenorphine Versus Morphine for Severe Pain in the Emergency Department
Lead Sponsor:
Alameda Health System
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study evaluates intravenous (IV) buprenorphine versus IV morphine for the management of severe, acute pain among emergency department (ED) patients. ED patients with severe pain will be randomize...
Detailed Description
Buprenorphine is classified as a partial mu opioid agonist and a weak kappa antagonist. In lower doses, buprenorphine has an analgesic potency 25 to 40 times more potent than similar milligram dosages...
Eligibility Criteria
Inclusion
- ED patients with acute pain NRS ≥7 warranting IV opioid analgesia (according to ED provider)
Exclusion
- Patient refusal
- pregnancy
- level 1 trauma patients
- patients deemed critically ill by provider
- patients in custody
- patients on methadone
- Patients who have received or taken any short acting opioid medication in the past 12 hours.
- Patients who have received or taken any long acting opioid medication in the past 24 hours.
Key Trial Info
Start Date :
September 26 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2018
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT03256487
Start Date
September 26 2017
End Date
July 1 2018
Last Update
October 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alameda Health System, Highland Hospital
Oakland, California, United States, 94602